163 related articles for article (PubMed ID: 32504922)
1. Staurosporine and venetoclax induce the caspase-dependent proteolysis of MEF2D-fusion proteins and apoptosis in MEF2D-fusion (+) ALL cells.
Tange N; Hayakawa F; Yasuda T; Odaira K; Yamamoto H; Hirano D; Sakai T; Terakura S; Tsuzuki S; Kiyoi H
Biomed Pharmacother; 2020 Aug; 128():110330. PubMed ID: 32504922
[TBL] [Abstract][Full Text] [Related]
2. YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma.
Kojima Y; Hayakawa F; Morishita T; Sugimoto K; Minamikawa Y; Iwase M; Yamamoto H; Hirano D; Imoto N; Shimada K; Okada S; Kiyoi H
Pharmacol Res; 2017 Jun; 120():242-251. PubMed ID: 28396094
[TBL] [Abstract][Full Text] [Related]
3. Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity.
Hirano D; Hayakawa F; Yasuda T; Tange N; Yamamoto H; Kojima Y; Morishita T; Imoto N; Tsuzuki S; Mano H; Naoe T; Kiyoi H
Oncogene; 2019 Mar; 38(13):2263-2274. PubMed ID: 30478446
[TBL] [Abstract][Full Text] [Related]
4. The pathogenic role of MEF2D-SS18 fusion gene in B-cell acute lymphoblastic leukemia.
Zhang M; Mao D; Zhang W
Biochem Biophys Res Commun; 2018 Feb; 496(4):1331-1336. PubMed ID: 29408457
[TBL] [Abstract][Full Text] [Related]
5. Clinical and molecular characteristics of
Ohki K; Kiyokawa N; Saito Y; Hirabayashi S; Nakabayashi K; Ichikawa H; Momozawa Y; Okamura K; Yoshimi A; Ogata-Kawata H; Sakamoto H; Kato M; Fukushima K; Hasegawa D; Fukushima H; Imai M; Kajiwara R; Koike T; Komori I; Matsui A; Mori M; Moriwaki K; Noguchi Y; Park MJ; Ueda T; Yamamoto S; Matsuda K; Yoshida T; Matsumoto K; Hata K; Kubo M; Matsubara Y; Takahashi H; Fukushima T; Hayashi Y; Koh K; Manabe A; Ohara A;
Haematologica; 2019 Jan; 104(1):128-137. PubMed ID: 30171027
[TBL] [Abstract][Full Text] [Related]
6. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling.
Seyfried F; Demir S; Hörl RL; Stirnweiß FU; Ryan J; Scheffold A; Villalobos-Ortiz M; Boldrin E; Zinngrebe J; Enzenmüller S; Jenni S; Tsai YC; Bornhauser B; Fürstberger A; Kraus JM; Kestler HA; Bourquin JP; Stilgenbauer S; Letai A; Debatin KM; Meyer LH
Cell Death Dis; 2019 Jul; 10(8):571. PubMed ID: 31358732
[TBL] [Abstract][Full Text] [Related]
7. Spatiotemporal activation of caspase-dependent and -independent pathways in staurosporine-induced apoptosis of p53wt and p53mt human cervical carcinoma cells.
Nicolier M; Decrion-Barthod AZ; Launay S; Prétet JL; Mougin C
Biol Cell; 2009 Jun; 101(8):455-67. PubMed ID: 19216720
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative potential of a novel parthenin analog P16 as evident by apoptosis accompanied by down-regulation of PI3K/AKT and ERK pathways in human acute lymphoblastic leukemia MOLT-4 cells.
Goswami A; Shah BA; Kumar A; Rizvi MA; Kumar S; Bhushan S; Malik FA; Batra N; Joshi A; Singh J
Chem Biol Interact; 2014 Oct; 222():60-7. PubMed ID: 25196075
[TBL] [Abstract][Full Text] [Related]
9. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
Karvonen H; Perttilä R; Niininen W; Hautanen V; Barker H; Murumägi A; Heckman CA; Ungureanu D
Oncogene; 2019 Apr; 38(17):3288-3300. PubMed ID: 30631148
[TBL] [Abstract][Full Text] [Related]
10. Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells.
Sun WJ; Huang H; He B; Hu DH; Li PH; Yu YJ; Zhou XH; Lv Z; Zhou L; Hu TY; Yao ZC; Lu MD; Shen X; Zheng ZQ
Biochem Pharmacol; 2017 Mar; 127():90-100. PubMed ID: 28012958
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
13. Functional, structural, and molecular characterizations of the leukemogenic driver MEF2D-HNRNPUL1 fusion.
Zhang M; Zhang H; Li Z; Bai L; Wang Q; Li J; Jiang M; Xue Q; Cheng N; Zhang W; Mao D; Chen Z; Huang J; Meng G; Chen Z; Chen SJ
Blood; 2022 Sep; 140(12):1390-1407. PubMed ID: 35544603
[TBL] [Abstract][Full Text] [Related]
14. K(ATP) channel block prevents proteasome inhibitor-induced apoptosis in differentiated PC12 cells.
Nam YJ; Lee DH; Lee MS; Lee CS
Eur J Pharmacol; 2015 Oct; 764():582-591. PubMed ID: 26142827
[TBL] [Abstract][Full Text] [Related]
15. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.
Gu Z; Churchman M; Roberts K; Li Y; Liu Y; Harvey RC; McCastlain K; Reshmi SC; Payne-Turner D; Iacobucci I; Shao Y; Chen IM; Valentine M; Pei D; Mungall KL; Mungall AJ; Ma Y; Moore R; Marra M; Stonerock E; Gastier-Foster JM; Devidas M; Dai Y; Wood B; Borowitz M; Larsen EE; Maloney K; Mattano LA; Angiolillo A; Salzer WL; Burke MJ; Gianni F; Spinelli O; Radich JP; Minden MD; Moorman AV; Patel B; Fielding AK; Rowe JM; Luger SM; Bhatia R; Aldoss I; Forman SJ; Kohlschmidt J; Mrózek K; Marcucci G; Bloomfield CD; Stock W; Kornblau S; Kantarjian HM; Konopleva M; Paietta E; Willman CL; Loh ML; Hunger SP; Mullighan CG
Nat Commun; 2016 Nov; 7():13331. PubMed ID: 27824051
[TBL] [Abstract][Full Text] [Related]
16. MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents.
Suzuki K; Okuno Y; Kawashima N; Muramatsu H; Okuno T; Wang X; Kataoka S; Sekiya Y; Hamada M; Murakami N; Kojima D; Narita K; Narita A; Sakaguchi H; Sakaguchi K; Yoshida N; Nishio N; Hama A; Takahashi Y; Kudo K; Kato K; Kojima S
J Clin Oncol; 2016 Oct; 34(28):3451-9. PubMed ID: 27507882
[TBL] [Abstract][Full Text] [Related]
17. Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation.
Stepczynska A; Lauber K; Engels IH; Janssen O; Kabelitz D; Wesselborg S; Schulze-Osthoff K
Oncogene; 2001 Mar; 20(10):1193-202. PubMed ID: 11313863
[TBL] [Abstract][Full Text] [Related]
18. Detection of caspase activation in situ by fluorochrome-labeled caspase inhibitors.
Amstad PA; Yu G; Johnson GL; Lee BW; Dhawan S; Phelps DJ
Biotechniques; 2001 Sep; 31(3):608-10, 612, 614, passim. PubMed ID: 11570504
[TBL] [Abstract][Full Text] [Related]
19. Caspase and proteasome activity during staurosporin-induced apoptosis in lens epithelial cells.
Andersson M; Sjöstrand J; Petersen A; Honarvar AK; Karlsson JO
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2623-32. PubMed ID: 10937575
[TBL] [Abstract][Full Text] [Related]
20. The phosphoinositide-dependent protein kinase 1 inhibitor, UCN-01, induces fragmentation: possible role of metalloproteinases.
Alcántara-Hernández R; Hernández-Méndez A; García-Sáinz JA
Eur J Pharmacol; 2014 Oct; 740():88-96. PubMed ID: 25016091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
